A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Latest Information Update: 01 Aug 2024
Price :
$35 *
At a glance
- Drugs VC 005 (Primary) ; Tofacitinib
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
- 29 Jul 2024 Status changed from recruiting to completed.
- 11 Aug 2023 Status changed from not yet recruiting to recruiting.
- 21 Apr 2023 New trial record